Celanese (CE) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
16 Oct, 2026Executive summary
Q2 adjusted EPS was $2.45, with $140 million in free cash flow; FY 2026 adjusted EPS guidance of ~$6 and free cash flow guidance of $700 million-$800 million were reaffirmed.
Net sales rose 9% year-over-year to $2.75 billion, supported by higher pricing and favorable currency; Q2 earnings benefited from supply-chain agility and reliable delivery.
Strategic priorities include cost reductions, footprint optimization, divestitures and deleveraging, alongside growth in medical, electronics and AI infrastructure.
Financial highlights
Adjusted EBIT was $470 million, with a 17% margin; operating profit was $276 million, up 19% year-over-year.
Free cash flow was $140 million despite nearly $200 million of working-capital cash use; first-half working-capital cash use was nearly $300 million.
Engineered Materials adjusted EBIT was $234 million and Acetyl Chain adjusted EBIT was $321 million.
Q2 adjusted EPS was $2.45, the highest in nearly three years; net earnings attributable to shareholders were $125 million and diluted EPS was $1.13.
Gross profit rose to $618 million from $534 million year-over-year; operating margin increased to 10.0% from 9.1%.
Outlook and guidance
Q3 adjusted EPS guidance is $1.35-$1.75; Lanaken-related inventory absorption, lower Ibn Sina equity earnings and higher raw-material costs weigh on the outlook.
FY 2026 adjusted EPS guidance remains ~$6, and free cash flow guidance remains $700 million-$800 million; working capital is expected to be neutral to slightly positive for 2026.
Engineered Materials adjusted EBIT is expected to grow at a double-digit rate in 2026, closer to 15% than 10%, despite absorption, divestiture and equity-earnings headwinds.
Planned cost reductions include $80 million-$100 million in 2027 and $140 million-$180 million cumulatively across 2026-2027; further actions remain under consideration.
2026 capital expenditures are projected at $300 million-$350 million; moderation in earnings is expected in H2 as supply normalizes and inventory actions continue.
Latest events from Celanese
- Sales and operating profit grew, but financing costs and restructuring drove a $253 million loss.CE
Q4 2004 - Pricing and productivity lifted FY 2005 profit, but leverage and input-cost risks persisted.CE
Q4 2005 - Pricing and productivity lifted FY 2006 operating profit 30.3% to $747M.CE
Q4 2006 - Pricing and currency lifted sales 12%, while outages, costs and refinancing weighed on results.CE
Q4 2007 - Recession cut earnings, but cash improved and recovery was expected in 2010.CE
Q4 2009 - Recovery lifted sales and operating profit; 2011 growth was expected across all segments.CE
Q4 2010 - FY11 earnings grew on pricing and mix, while major capacity and ethanol investments set up the next growth phase.CE
Q4 2011 - Acetyl pricing and currency dragged FY12 results; 12%–14% earnings growth targeted for FY13.CE
Q4 2012 - A $742 million relocation gain drove record reported profit amid mixed segment trends.CE
Q4 2013 - Sales and adjusted EPS advanced as record cash flow funded growth and shareholder returns.CE
Q4 2014